Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH-120 Nasal Spray for COVID-19 Post-Exposure Prophylaxis
NCT05747677Completed
- Sponsor
- Beijing Ditan Hospital
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of HH-120 in coronavirus disease 2019 (COVID-19), sponsored by Beijing Ditan Hospital. Primary endpoint: The proportion of subjects infected with SARS-CoV-2. Started Jun 2022; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05747677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747677.